New Consensus Report Recommends Individualized Eating Plan to Meet Each Person’s Goals, Life Circumstances and Health Status in diabetes

Personalized nutrition plans, nutrition for optimal weight management, and the prevention and management of diabetes complications including cardiovascular and kidney disease and gastroparesis, are detailed in the new guidance document, Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report (Consensus Report), produced by a panel of experts assembled by the American Diabetes Association (ADA). The Consensus

Read More


USC-led advance in groundbreaking cancer treatment eliminates severe side effects

An advance in the groundbreaking cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, a new USC study shows. “This is a major improvement,” said Si-Yi Chen of the USC Norris Comprehensive Cancer Center, professor in the Department of Molecular Microbiology

Read More


Synthetic Speech Generated from Brain Recordings

A state-of-the-art brain-machine interface created by UC San Francisco neuroscientists can generate natural-sounding synthetic speech by using brain activity to control a virtual vocal tract – an anatomically detailed computer simulation including the lips, jaw, tongue and larynx. The study was conducted in research participants with intact speech, but the technology could one day restore the

Read More


UK named the ‘heartland of European healthcare AI’ in new report

Germany and France are two flourishing AI hubs, but the UK has been named the European AI “powerhouse” in a new report from London-based investment firm MMC Ventures. Published earlier this month, the analysis sheds light on the hype around the technology, but identifies healthcare as an area of increasing focus for AI entrepreneurs as systems

Read More


Stem cells show promise for acute-on-chronic liver failure

 Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced clinical data from the ongoing phase 2a study of its lead product candidate HepaStem® in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF. The data was presented in an oral presentation during the

Read More